SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo takes aim at Hard-to-Treat brain lymphoma
Disease control OngoingThis study tests a combination of six drugs (TEDDI-R) for people whose aggressive B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this mix can control the cancer better than current treatments. About 48 adults with relapsed or refractory disease will…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New antibody targets Hard-to-Treat brain lymphoma
Disease control OngoingThis study tests a new drug called GNC-038 in people with a type of brain lymphoma that has returned or not responded to treatment. The goal is to find a safe dose and see if the drug can shrink tumors. About 7 adults will take part in this early-phase trial.
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC